07:19 EST Vanda Pharmaceuticals (VNDA) files $200M mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals reports Q4 EPS ($2.39) vs. (8c) last year
- Vanda Pharmaceuticals sees FY26 revenue $230M-$260M, consensus $271.27M
- VNDA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Vanda Pharmaceuticals Advances Ponesimod Into Phase 3 Psoriasis Study: What Investors Should Know
- Maintaining Buy Rating on Vanda: Limited Impact from Tasimelteon Setback, Ongoing FDA Engagement, and Bysanti Catalyst Support $22 Target